期刊文献+

从药物的三维分子结构预测人体小肠吸收(英文) 被引量:1

Predicting Human Intestinal Absorption from Threedimensional Molecular Structure of Drugs
下载PDF
导出
摘要 在口服药物的发展过程中,人体小肠吸收的预测是候选药物设计、优化和选择的一个主要目标.VolSurf/GRID计算方法作为一个新的工具被用来预测被测化合物的人体小肠吸收,以及测定人体小肠吸收所必需的重要的分子特征.被测化合物包括112个结构不同的类似药物的化合物.使用偏最小二乘判别分析方法在实验数据和人体小肠吸收的理论分子特征之间建立相关性.建立的两个模型之间具有较高的一致性.小肠吸收实验数据与分子特征之间好的相关性(r2=0.82,q2=0.67)表明,从化合物的三维分子结构能够预测人体小肠吸收.有利于人体小肠吸收的药物分子特征包括,分子量中心与亲水区重心的不平衡性,较大的疏水区域以及分子内较少的氢键给体. The prediction of human intestinal absorption is a major goal in the design, optimization, and selection of candidates for the development of oral drugs. A computerized method (VolSurf/GRID) was used as a novel tool for predicting human intestinal absorption of test compound, and for determining the critical molecular properties needed for human intestinal absorption. The tested molecules consisted of 112 diverse drug-like compounds. Partial least squares discriminant analysis was used to correlate the experimental data with the theoretical molecular properties of human intestinal absorption. There was high consistency between two built models. A good correlation (r(2) = 0.82, q(2) = 0.67) between the molecular properties and the experimental data demonstrated that human intestinal absorption could be predicted front the three-dimensional molecular structure of a compound. Favorable structural properties identified for the potent intestinal absorption drugs included strong imbalance between the center of mass of a molecule and the barycenter of its hydrophilic and hydrophobic regions and a definitive hydrophobic region as well as less hydrogen bond donors on the molecule.
机构地区 浙江大学
出处 《物理化学学报》 SCIE CAS CSCD 北大核心 2004年第5期512-517,共6页 Acta Physico-Chimica Sinica
基金 国家自然科学基金(20173050)资助项目 ~~
关键词 口服药物 三维分子结构 人体 小肠 偏最小二乘法 PLS human intestinal absorption (HIA) three-dimension VolSurf principal component analysis (PCA) partial least squares (PLS)
  • 相关文献

参考文献18

  • 1Martin, Y. C. J. Med. Chem., 1981, 24:229
  • 2Testa, B.; Carrupt, P. -A.; Gaillard, P.; Billois, F.; Weber, P.Pharm. Res., 1996, 11:335
  • 3Rubas, W.; Cromwell, M. E. M. Adv. Drug Deliv. Rev., 1997, 23:157
  • 4Lee, C. -P.; de Vrueh, R. L. A.; Smith, P. L. Adv. Drug Deliv.Rev., 1997, 23:47
  • 5Cruciani, G.; Pastor, M.; Guba, W. Eur. J. Pharm. Sci., 2000, 11(Suppl. 2 ): S29
  • 6Tarvainen, M.; Sutinen, R.; Somppi, M.; Paronen, P.; Poso, A.Pharm. Res., 2001, 18:1760
  • 7Cruciani, G.; Crivori, P.; Carrupt, P. -A.; Testa, B. J. Mol.Struct. (Theochem), 2000, 503:17
  • 8Filipponi, E.; Cruciani, G.; Tabarrini, O.; Cecchetti, V.; Fravolini,A. J. Comput. -Aided Mol. Design, 2001, 15:203
  • 9Crivori, P.; Cruciani, G.; Carrupt, P. -A.; Testa, B. J. Med.Chem., 2000, 43: 2204
  • 10Alifrangis, L. H.; Christensen, I. T.; Berglund, A.; Sandberg,M.; Hovgaard, L.; Frokjaer, S. J. Med. Chem., 2000, 43:103

同被引文献25

  • 1Abildstrom, S. Z.; Rasmussen, S.; Rosen, M.; Madsen, M. Heart, 2003, 89:507
  • 2Barter, P. J.; Kastelein, J. J. P. J. Am. Coll. Cardiol., 2006, 47:492
  • 3Ong, H. T. Q. QJM -An Int. J. Med., 2005, 98:599
  • 4Shinkai, H. Mini Rev. Med. Chem., 2002, 2:271
  • 5Carlquist, J.; Anderson, J. L. Curr. Opin. Cardiol., 2007, 22:352
  • 6Chapman, M. J. Pharmacol. Therapeut., 2006, 111: 893
  • 7Milani, R. V.; Lavie, C. J. O. J. Am. Coll. Cardiol., 2006, 48:1791
  • 8Qiu, X.; Mistry, A.; Ammirati, M. J.; Chrunyk, B. A.; Clark, R. W. Cong, Y.; Culp, J. S.; Griffor, M. C.; Hawrylik, S. J.; Hayward, C. M.; Hensley, P.; Hoth, L. R.; Karam, G. A.; Lira, M. E.; Lloyd, D. B.; Mcgrath, K. M.; Stutzman-Engwall, K. J.; Subashi, A. K.; Subashi, T. A.; Thompson, J. F.; Wang, I. K.; Zhao, H.; Seddon, A. P. Nat. Struct. Mol. Biol., 2007, 14:106
  • 9Suzuki, M.; Wada, H.; Maeda, S.; Saito, K.; Minatoguchi, S.; Saito, K.; Seishima, M. Clin. Chem., 2005, 51:132
  • 10Jain, K. S.; Kathiravan, M. K.; Somani, R. S.; Shishoo, C. J. Bioorg. Med. Chem., 2007, 15:4674

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部